PMID- 12428065
OWN - NLM
STAT- MEDLINE
DCOM- 20030530
LR  - 20181130
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 66
IP  - 2
DP  - 2002
TI  - The clinical importance of proton pump inhibitor pharmacokinetics.
PG  - 67-78
AB  - Achieving the optimal clinical response for patients with upper gastrointestinal 
      peptic disease is important. This response depends on the pathology treated as 
      well as on the choice of proton pump inhibitor. Here, we identify factors in 
      specific disease therapy and proton pump inhibitor (PPI) pharmacokinetic and 
      pharmacodynamic characteristics that help us achieve this goal. These include 
      differences in PPI bioavailability and acid-suppressive effects. Available data 
      indicate that PPIs appear to have similar potency on a milligram basis, and that 
      omeprazole and lansoprazole are more frequently double dosed than pantoprazole. 
      The lower propensity for double dosing with pantoprazole may also result in lower 
      medication acquisition costs and a reduction in physician visits due to 
      ineffective therapy with the standard dosing of these other agents.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Yacyshyn, B R
AU  - Yacyshyn BR
AD  - Department of Medicine, Division of Gastroenterology, University of Alberta, 
      Edmonton, Canada. bruce.yacyshyn@med.va.gov
FAU - Thomson, A B R
AU  - Thomson AB
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Sulfoxides)
RN  - D8TST4O562 (Pantoprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Anti-Ulcer Agents/administration & dosage/*pharmacokinetics/therapeutic use
MH  - Benzimidazoles/administration & dosage/*pharmacokinetics/therapeutic use
MH  - Cost Savings
MH  - Duodenal Ulcer/*drug therapy/metabolism
MH  - Gastroesophageal Reflux/drug therapy/*metabolism
MH  - Humans
MH  - Omeprazole/administration & dosage/*pharmacokinetics/therapeutic use
MH  - Pantoprazole
MH  - *Proton Pump Inhibitors
MH  - Sulfoxides/administration & dosage/*pharmacokinetics/therapeutic use
RF  - 93
EDAT- 2002/11/13 04:00
MHDA- 2003/05/31 05:00
CRDT- 2002/11/13 04:00
PHST- 2002/11/13 04:00 [pubmed]
PHST- 2003/05/31 05:00 [medline]
PHST- 2002/11/13 04:00 [entrez]
AID - 65588 [pii]
AID - 10.1159/000065588 [doi]
PST - ppublish
SO  - Digestion. 2002;66(2):67-78. doi: 10.1159/000065588.